Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200 at the European Congress of Rheumatology (EULAR 2026) in London, UK, from June 3-6, 2026. The data, from healthy participants, indicate that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. This targeted approach aims to maximize anti-inflammatory effects while minimizing the systemic side effects typically associated with glucocorticoid therapy, such as cortisol suppression and other toxicities. The Phase 1 study is ongoing, with dosing of patients suffering from moderate to severe rheumatoid arthritis (RA). Data from this patient cohort are expected by year-end 2026.
The initial results presented at EULAR 2026 are significant as they suggest that LFD-200 could offer a safer alternative to current glucocorticoid treatments, which are widely used but limited by their side effect profile. If successful in patients with RA, LFD-200 could potentially transform the management of autoimmune and inflammatory diseases by providing effective anti-inflammatory control without the burden of systemic toxicity. This would be particularly impactful for patients who require long-term treatment and are at risk of developing serious complications from chronic glucocorticoid use.
Lifordi is leveraging the success of ADCs, a technology proven in oncology, to address unmet needs in immunology. The company’s approach involves conjugating a potent glucocorticoid payload to an antibody that targets specific immune cells, thereby concentrating the drug at the site of inflammation. Beyond LFD-200, Lifordi has applied its novel drug delivery platform to other payloads, including antisense oligonucleotides (ASOs), siRNA, and small molecules, broadening the potential applications of its technology.
Lifordi is backed by prominent investors, including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, reflecting confidence in its platform and pipeline. The company is committed to changing how immune and inflammatory diseases are treated, as noted in its press release. For more information, visit www.lifordi.com.
The Phase 1 data presented at EULAR 2026 are a critical step forward in validating the potential of LFD-200. With patient dosing ongoing and results expected later this year, the rheumatology community awaits further evidence of this ADC's efficacy and safety profile. If the positive trends observed in healthy participants translate to patients, LFD-200 could become a valuable addition to the treatment armamentarium for RA and potentially other inflammatory conditions.
